PHARMACEUTICAL COMPOSITE CAPSULE FORMULATION COMPRISING IRBESARTAN AND HMG-COA REDUCTASE INHIBITOR
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Aug 20, 2015
app pub date -
Aug 30, 2013
filing date -
Aug 31, 2012
priority date (Note) -
Published
status (Latency Note)
Importance
Abstract
Disclosed are a pharmaceutical composite capsule formulation comprising 1) an independent irbesartan unit comprising irbesartan or a pharmaceutically acceptable salt thereof; and 2) an independent HMG-CoA reductase inhibitor unit comprising an HMG-CoA reductase inhibitor or a pharmaceutically acceptable salt thereof, and an alkaline additive, wherein said independent units are separated from each other within a capsule, and a method for preparing the same. Designed to prevent an interaction between irbesartan and the HMG-CoA reductase inhibitor, the pharmaceutical composite capsule formulation is improved in stability and dissolution rate, and thus shows great bioavailability. In addition, the formulation is expected to guarantee high drug compliance owing to its small size, and therefore can be applied to the treatment of hypertension and hypercholesterolemia.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully